id: NEW:systemic_glycine_treatment_to_NEW:voluntary_ethanol_intake
name: Systemic Glycine Treatment â†’ Voluntary Ethanol Intake
from_node:
  node_id: NEW:systemic_glycine_treatment
  node_name: Systemic Glycine Treatment
to_node:
  node_id: NEW:voluntary_ethanol_intake
  node_name: Voluntary Ethanol Intake
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Systemic glycine treatment elevates central glycine levels in the nucleus accumbens'
- 'Step 2: Elevated glycine activates glycine receptors (GlyR) in the dopamine reward pathway'
- 'Step 3: GlyR activation modulates the reward signal typically enhanced by ethanol'
- 'Step 4: Reduced reward signaling decreases motivation for ethanol consumption'
- 'Step 5: Voluntary ethanol intake and preference decrease in treated animals'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Y. Olsson et al. 2020. "Effects of systemic glycine on accumbal glycine and dopamine
    levels and ethanol intake in male Wistar rats." https://doi.org/10.1007/s00702-020-02284-x
  supporting_citations:
  - Abstract references GlyT-1 inhibitor studies repeatedly showing decreased ethanol intake
  - Abstract references prior work on pharmacotherapy targeting ethanol-dopamine pathway mechanisms
  - Additional citations require full-text access
  doi: 10.1007/s00702-020-02284-x
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Systemic glycine treatment reduces voluntary ethanol intake and preference by modulating
  the glycinergic-dopaminergic reward pathway in the nucleus accumbens, suggesting a potential pharmacological
  treatment principle for alcohol use disorder.
moderators:
- name: glycine_dose
  direction: strengthens
  strength: moderate
  description: Intermediate dose of glycine was effective in reducing ethanol intake and preference
structural_competency:
  equity_implications: This preclinical finding supports development of novel AUD treatments targeting
    the glycinergic system. Current AUD medications have modest effect sizes, creating treatment gaps
    that disproportionately affect populations with limited access to comprehensive addiction services.
    Expanding effective pharmacotherapy options could help address these structural barriers to AUD treatment.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.142126'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
